As part of the contract, Los Angeles-based ImaginAb will provide Pfizer will its 89Zr CD8 immuno-PET agent, which is used to image CD8 T cells in cancer patients.
The new approach relies on radiomic CT data combined with ultrasound imaging to create a visual guide for doctors, researchers explained in European Radiology.